Success Metrics

Clinical Success Rate

71.4%

Based on 5 completed trials

Completion Rate

71%(5/7)

Active Trials

0(0%)

Results Posted

80%(4 trials)

Terminated

2(25%)

Phase Distribution

Ph phase_3

13%

Ph not_applicable

13%

Ph phase_1

13%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

4(57.1%)

Phase 3Large-scale testing

1(14.3%)

N/ANon-phased studies

1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(3)

Detailed Status

Completed5

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

71.4%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (14.3%)

Phase 24 (57.1%)

Phase 31 (14.3%)

N/A1 (14.3%)

Trials by Status

withdrawn113%

terminated225%

completed563%

Recent Activity

0 active trials

Showing 5 of 8

completed

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

NCT04069299

completednot_applicable

Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study

NCT02726906

withdrawnphase_2

68-Ga-FAPI PET Imaging in Malignancy

NCT04023240

terminatedphase_1

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630

completedphase_2

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT04069299

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Completed

NCT02726906Not Applicable

Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study

Completed

NCT04023240Phase 2

68-Ga-FAPI PET Imaging in Malignancy

Withdrawn

NCT03958630Phase 1

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

Terminated

NCT00375830Phase 2

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Completed

NCT02440308Phase 2

68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer

Completed

NCT00123760Phase 2

Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer

Completed

NCT01141764Phase 3

Cerebral Metabolic Changes Associated With Thalamic Stimulation

Terminated

All 8 trials loaded

Drug Details

Intervention Type: DIAGNOSTIC TEST
Total Trials: 8